Anemia Due to Chemotherapy
Understanding Anemia Due to Chemotherapy: This resource provides information on Chemotherapy-Induced Anemia, including clinical documentation, medical coding, and healthcare implications. Learn about Anemia from Chemotherapy, its diagnosis, and management for optimal patient care. This is a valuable resource for healthcare professionals, medical coders, and those seeking information on anemia related to chemotherapy treatment.
Low red blood cell count caused by chemotherapy drugs.
Fatigue, weakness, shortness of breath, pale skin, dizziness, fast heart rate.
Oncology clinics, hospitals, cancer treatment centers.
ICD-10 Code Families
Complete code families applicable to D64.81
When to use each related code
| Description | When to use |
|---|---|
| Low red blood cell count due to chemotherapy. | Use when anemia is a direct result of chemotherapy treatment. Consider stage and severity. |
| Low red blood cell count due to blood loss. | Use when anemia is caused by acute or chronic blood loss. Specify source of bleeding. |
| Low red blood cell count from iron deficiency. | Use when anemia is due to insufficient iron for red blood cell production. Identify underlying cause. |
Best-practice checklist
- ✓Document type and date of chemotherapy
- ✓Hemoglobin/hematocrit levels pre and post chemo
- ✓Signs/symptoms of anemia (fatigue, pallor)
- ✓Anemia severity (mild, moderate, severe)
- ✓ICD-10 code D64.81, other ext. cause anemia
Common pitfalls to avoid
Coding anemia without specifying the type (e.g., aplastic, hemolytic) can lead to inaccurate reimbursement and quality reporting. CDI crucial for clarification.
Incorrect sequencing of chemotherapy and anemia codes can impact DRG assignment. Accurate coding reflects the causal relationship. Compliance risk.
Chemotherapy-induced anemia often co-occurs with neutropenia. Missing neutropenia diagnoses impacts severity and resource utilization tracking. Coding audits essential.
Best-practice tips
- 01Monitor hemoglobin/hematocrit (ICD-10-CM D63.0). Optimize CDI.
- 02Consider erythropoiesis-stimulating agents (ESAs) per guidelines (NCCN). Document ESA response.
- 03Manage iron levels. Check ferritin/transferrin (ICD-10-CM D50.9). Document iron therapy.
- 04Transfuse packed red blood cells (PRBCs) judiciously. Document transfusion indications (ICD-10-CM D64.9).
- 05Educate patient on anemia management. Document in chart for compliance.
Step-by-step checklist
- 1
Confirm recent chemotherapy treatment documented.
- 2
Hb/Hct below normal range? Review CBC.
- 3
Evaluate for other anemia causes (iron, B12).
- 4
Document anemia severity and attribution to chemo.
Ready-to-paste narrative
Patient presents with symptoms consistent with chemotherapy-induced anemia (CIA), a common side effect of cancer treatment. The patient's recent chemotherapy regimen, documented in their oncology treatment summary, includes [Specific Chemotherapy Agents Used - e.g., carboplatin and paclitaxel]. Presenting symptoms include fatigue, weakness, pallor, and shortness of breath (dyspnea), correlating with laboratory findings. Complete blood count (CBC) reveals decreased hemoglobin (Hb) and hematocrit (Hct) levels, falling below the established reference range. The patient's current hemoglobin level is [Hb Value] g/dL, and hematocrit is [Hct Value]%. Mean corpuscular volume (MCV) is [MCV Value] fL, indicating [normocytic, microcytic, or macrocytic] anemia. These findings support a diagnosis of anemia secondary to chemotherapy. Differential diagnoses considered include iron deficiency anemia and anemia of chronic disease, but the temporal relationship to chemotherapy administration and the patient's oncology history makes chemotherapy-induced anemia the most likely diagnosis. The patient's current performance status, as assessed by the Eastern Cooperative Oncology Group (ECOG) scale, is [ECOG Performance Status]. Treatment plan includes monitoring hemoglobin and hematocrit levels, and consideration for red blood cell (RBC) transfusion if clinically indicated based on symptoms and Hb levels. Patient education provided regarding management of anemia symptoms, including energy conservation strategies and dietary recommendations. Follow-up scheduled in [Duration - e.g., two weeks] to reassess hemoglobin levels and overall response to management. ICD-10 code D63.0, Anemia due to antineoplastic chemotherapy, is applicable.
Common questions and answers
What are the best evidence-based strategies for managing chemotherapy-induced anemia in adult cancer patients?+
Managing chemotherapy-induced anemia (CIA) requires a multifaceted approach tailored to the individual patient's needs and overall clinical picture. Evidence-based strategies include regular monitoring of hemoglobin levels, optimizing iron stores through oral or intravenous iron supplementation as needed, considering the use of erythropoiesis-stimulating agents (ESAs) like epoetin alfa or darbepoetin alfa in select patients based on current guidelines, and ensuring adequate nutritional support to promote red blood cell production. Transfusion of red blood cells may be necessary in cases of severe anemia or symptomatic patients. Consider implementing a patient blood management program to minimize unnecessary transfusions. Explore how recent clinical trials and guidelines influence ESA usage in various cancer types to optimize your treatment approach. Learn more about the potential benefits and risks of ESAs in specific patient populations.
How can I differentiate anemia due to chemotherapy from other causes of anemia in a patient undergoing cancer treatment?+
Differentiating chemotherapy-induced anemia from other anemia causes in cancer patients requires a thorough evaluation. Consider factors such as the timing of anemia onset relative to chemotherapy initiation, the patient's medical history (including pre-existing anemia or other hematological conditions), and the presence of other symptoms. Anemia from chemotherapy typically develops gradually after treatment begins. Analyze the patient's complete blood count (CBC) looking for specific characteristics like decreased hemoglobin and hematocrit, along with other indicators like mean corpuscular volume (MCV) and reticulocyte count. Bone marrow biopsy may be helpful in certain cases to evaluate for other underlying causes of anemia. Consider reviewing recent research articles focusing on the diagnostic challenges and specific markers associated with chemotherapy-induced anemia. Explore the differential diagnosis of anemia in cancer patients to improve diagnostic accuracy.
What are the most common side effects associated with erythropoiesis-stimulating agents (ESAs) used to treat anemia from chemotherapy, and how should they be managed?+
Erythropoiesis-stimulating agents (ESAs) like epoetin alfa and darbepoetin alfa can be effective in treating chemotherapy-induced anemia, but clinicians should be aware of potential side effects. Common adverse events include hypertension, thromboembolic events (including deep vein thrombosis and pulmonary embolism), and, rarely, pure red cell aplasia. Careful monitoring of blood pressure and appropriate management of hypertension are crucial. Consider implementing prophylactic measures for thromboembolic events based on patient risk factors. Be aware of the potential for increased tumor growth in certain cancers and follow current guidelines regarding ESA usage. Learn more about the latest research on managing ESA-related side effects and explore the use of alternative treatment strategies for chemotherapy-induced anemia when ESAs are contraindicated or not tolerated.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.